• OPEN AN ACCOUNT
Indian Indices
Nifty
24,579.60 -45.45
(-0.18%)
Sensex
80,157.88 -206.61
( -0.26%)
Bank Nifty
53,661.00 -341.45
( -0.63%)
Nifty IT
35,737.90 -2.75
( -0.01%)
Global Indices
Nasdaq
45,565.88 -92.03
(-0.20%)
Dow Jones
6,481.26 -41.60
(-0.64%)
Hang Seng
42,288.11 99.32
(0.24%)
Nikkei 225
9,116.69 -79.65
(-0.87%)
Forex
USD-INR
88.15 0.55
(0.63%)
EUR-INR
103.00 0.84
(0.82%)
GBP-INR
118.99 0.66
(0.55%)
JPY-INR
0.60 0.00
(0.61%)

EQUITY - MARKET SCREENER

Clara Industries Ltd
Industry :  Packaging
BSE Code
ISIN Demat
Book Value()
543435
INE0JJS01014
20.7241848
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
40.66
76.49
EPS(TTM)
Face Value()
Div & Yield %
0.91
10
0
 

adani ports & special economic zone ltd
Glenmark USA to launch Eribulin Mesylate Injection, mg/2 mL (0.5 mg/mL) Single-Dose Vials
Sep 02,2025

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.

Glenmark's Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven® Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc., and the company will begin distribution in September 2025.

According to IQVIA® sales data for the 12-month period ending July 2025, the Halaven® Injection, 1 mg/2 mL (0.5 mg/mL) market achieved annual sales of approximately $66.3 million.